Artenga’s microbubble drug conjugates (MDCs) are key enablers for safe, non-invasive, targeted blood brain barrier drug delivery and for boosting immunotherapy efficacy without added toxicity using focused ultrasound (FUS). Our Sunnybrook Research Institute collaborators have done the first FUS and non drug microbubble BBB opening clinical trials for glioblastoma, Alzheimer’s, breast cancer, brain mets, ALS and Parkinson’s.

Differentiation:  Higher dose delivered with greater perfusion, liver clearance to mitigate systemic effects, AAV MDC and new tech planned to limit transduction to diseased brain regions.

Artenga Inc. Logo



Event details

Date: June 10 - 17, 2021

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


30 in total